Anti‐erythropoietin antibody–mediated pure red cell aplasia in a living donor liver transplant recipient treated for hepatitis C virus

Jordan M. Schecter, J. Gregory Mears, Bachir Alobeid, Paul J. Gaglio – 29 October 2007 – After liver transplantation, reinfection of the newly engrafted liver with hepatitis C virus is essentially universal in patients who are viremic at the time of transplantation. Treatment with interferon preparations with or without ribavirin is recommended in patients with marked histologic injury; however, hematologic toxicity associated with therapy has been reported, which is usually treated with growth factor support, including erythropoietin analogues.

Recurrent hepatic lymphangiomatosis after orthotopic liver transplantation

Seong H. Ra, Robert F. Bradley, Michael C. Fishbein, Ronald W. Busuttil, David S.K. Lu, Charles R. Lassman – 29 October 2007 – Hepatic lymphangiomatosis is a rare disease characterized by an abnormal lymphatic proliferation involving the liver alone, liver and spleen, or multiple organs. Hepatic lymphangiomatosis becomes symptomatic secondary to compression or replacement of the normal parenchyma, which can lead to liver failure. Resection and orthotopic liver transplantation (OLT) can be used as treatment for this disease.

Herpes simplex virus hepatitis: An analysis of the published literature and institutional cases

John P. Norvell, Andres T. Blei, Borko D. Jovanovic, Josh Levitsky – 27 September 2007 – Hepatitis is a rare complication of herpes simplex virus (HSV), often leading to acute liver failure (ALF), liver transplantation (LT), and/or death. Our aim was to identify variables associated with either survival or progression (death/LT), based on an analysis of cases in the literature and our institution. A total of 137 cases (132 literature, 5 institutional) of HSV hepatitis were identified. The main features at clinical presentation were fever (98%), coagulopathy (84%), and encephalopathy (80%).

Resistance to combined ganciclovir and foscarnet therapy in a liver transplant recipient with possible dual‐strain cytomegalovirus coinfection

John Rodriguez, Katherine Casper, Gregory Smallwood, Andrei Stieber, Carlos Fasola, Jennifer Lehneman, Thomas Heffron – 27 September 2007 – We present a case report of a cytomegalovirus (CMV)‐seronegative, 58‐year‐old male who received a CMV‐seropositive donor liver transplant without CMV prophylaxis. On postoperative day 30, the patient developed primary CMV disease that responded to ganciclovir. On postoperative day 114, however, he was diagnosed with recurrent CMV infection.

Subscribe to